Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Stock Short Interest Declines 63.0%

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Get Free Report) was the target of a significant decrease in short interest in October. As of October 30th, there was short interest totaling 5,139 shares, a decrease of 63.0% from the October 15th total of 13,889 shares. Based on an average trading volume of 48,290 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the company are short sold.

Chemomab Therapeutics Price Performance

NASDAQ:CMMB traded up $0.08 during trading hours on Monday, reaching $1.61. 17,583 shares of the company were exchanged, compared to its average volume of 93,786. The company has a market capitalization of $11.67 million, a P/E ratio of -0.76 and a beta of 0.80. Chemomab Therapeutics has a 1-year low of $0.92 and a 1-year high of $2.99. The business has a 50 day moving average of $1.65 and a 200 day moving average of $1.74.

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) last posted its quarterly earnings data on Thursday, August 20th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.12).

Wall Street Analysts Forecast Growth

CMMB has been the subject of several analyst reports. Weiss Ratings upgraded shares of Chemomab Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. Wall Street Zen raised shares of Chemomab Therapeutics to a “hold” rating in a report on Saturday, October 3rd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

View Our Latest Analysis on Chemomab Therapeutics

About Chemomab Therapeutics

(Get Free Report)

Chemomab Therapeutics is an Israel-based clinical-stage biopharmaceutical company developing treatments for inflammatory and fibrotic diseases. Its research focuses on CCL24, a signaling protein the company believes contributes to inflammation and tissue scarring. The company’s lead candidate, CM-101, is a monoclonal antibody designed to block CCL24. Chemomab has studied the candidate in conditions including primary sclerosing cholangitis and systemic sclerosis. Chemomab was previously a privately held company and became publicly traded in 2021 through a merger with Anchiano Therapeutics.

Further Reading

Receive News & Ratings for Chemomab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemomab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.